

SUCCESSFUL COMPLETION OF SHARE PURCHASE PLAN

Melbourne, Australia – 13 November 2024: Percheron Therapeutics Limited (ASX: PER or ‘the Company’), an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce successful completion of the Company’s Share Purchase Plan (SPP) that was launched on 28 October 2024¹ to raise up to a maximum of AUD\$2 million.

Key Points

- The SPP followed a two-tranche placement to sophisticated and institutional investors that received commitments representing \$13 million in gross proceeds. The first tranche of \$10.8 million was completed on 24 October 2024, with a second tranche of \$2.2 million subject to the Company refreshing its placement capacity at the Percheron Therapeutics Annual General Meeting to be held on 21 November 2024.²
- The intent of the SPP was to provide an equitable opportunity for existing shareholders to purchase stock in the Company on the same terms as institutional participants.
- The Company has received 201 applications, totalling \$1.85 million in gross proceeds. As a result, it is expected that 23,160,916 new shares will be allotted on Friday 15 November 2024, with all subscriptions honoured in full.

“We consider it an important matter of equity that retail holders are able to purchase stock on the same terms as institutional investors, and so our general preference is for institutional placements to be accompanied by corresponding facilities for existing retail holders,” commented Percheron CEO, Dr James Garner. “We are delighted that 201 shareholders have chosen to participate on this occasion. While the previous institutional placement has funded the Company into CY2026 based on current activities, the incremental funds from the SPP will allow us to support and augment some valuable additional activities, including the post-trial access program that was announced on 28 October 2024, and further engagement with patient advocacy. With our financing activities now substantially complete, we look forward to reporting initial data from our ongoing international phase IIb clinical trial of avicursen (ATL1102) in Duchenne muscular dystrophy in December.”

~ ENDS ~

¹ <https://per.live.irmau.com/pdf/80896794-c4b3-471c-80c4-fc0f5d8cfa8/Share-Purchase-Plan-Offer-Booklet.pdf>

² <https://per.live.irmau.com/pdf/5de4b0e9-81c2-4bb4-b84d-a950ac405795/130-million-Institutional-Placement.pdf>

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

*This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.*
